Skip to main content

Disruptive technologies for effectively rehabilitating chronic ambulatory disability

Objectif

Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder
(stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in
Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular diseases (4 million),
spinal cord injury (paraplegia and quadriplegia, 3 million) and spina bifida (3 million).
Neurological disorders affect the lower motor of the nervous system and share the progressive muscle weakness, which
lead to several walk disability, loss of autonomy and psychosocial consequences. Most therapeutic treatments are limited to
medicines and musculoskeletal rehabilitation programs, which are very expensive and limited to 15-30 min/week
rehabilitation sessions.
Active lifestyle is the most effective measure to restore the physical conditions. But the loss of muscle strength impedes the
ambulatory function. The need is for a device allowing them walking effortlessly and safely in the everyday life activities.
Based on our ARES technology, -the minimal functional unit providing synchronized joints-muscles mobility- Marsi Bionics
has developed powered orthoses for in-house rehabilitation of patients affected by muscle weakness disorders, showing a
product portfolio that covers the needs of a wide range of Neurological Disorders. Marsi products will be commercialized
under renting models allowing patients acquiring it for daily use. This technology will improve these patients life quality and
enlarge life expectancy by avoiding critical health complications of losing walking ability.
Marsi is strengthened by joining with a leading company in the current industrial market, ESCRIBANO. This alliance in the
frame of SME Phase 2 will speed up industrialization, overcome the certification barrier and minimize the time to market. As
a result, we expect to reach above 36M€ turnover in 2023 and 81 generated jobs.

Appel à propositions

H2020-SMEInst-2016-2017

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-2-2016-2017

Régime de financement

SME-2 - SME instrument phase 2

Coordinateur

MARSI BIONICS SL
Contribution nette de l'UE
€ 1 560 930,00
Adresse
Calle Rue Del Percebe 30
28521 Rivas Vaciamadrid
Espagne
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contribution hors UE
€ 668 970,00

Participants (1)

Tiers

Entité juridique autre qu’un sous-traitant qui est affiliée ou juridiquement liée à un participant. L’entité réalise des travaux dans les conditions prévues par la convention de subvention, fournit des biens ou des services pour l’action, mais n’a pas signé la convention de subvention. Le tiers respecte les règles applicables au participant qui lui est lié dans le cadre de la convention de subvention en ce qui concerne l’éligibilité des coûts et le contrôle des dépenses.

ESCRIBANO MECHANICAL AND ENGINEERING SL
Espagne
Contribution nette de l'UE
€ 79 800,00
PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Adresse
Avda Punto Es 10 Parque Cientifico Tecnologico
28805 Alcalá De Henares
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contribution hors UE
€ 189 450,00